No connection

Search Results

FOLD vs LNTH

FOLD
Amicus Therapeutics, Inc.
BEARISH
Price
$14.47
Market Cap
$4.54B
Sector
Healthcare
AI Confidence
85%
LNTH
Lantheus Holdings, Inc.
NEUTRAL
Price
$80.59
Market Cap
$5.25B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
FOLD
--
LNTH
23.63
Forward P/E
FOLD
17.67
LNTH
12.81
P/B Ratio
FOLD
16.41
LNTH
4.78
P/S Ratio
FOLD
7.16
LNTH
3.4
EV/EBITDA
FOLD
111.86
LNTH
14.31

Profitability

Gross Margin
FOLD
88.5%
LNTH
61.1%
Operating Margin
FOLD
8.61%
LNTH
19.07%
Profit Margin
FOLD
-4.28%
LNTH
15.15%
ROE
FOLD
-11.58%
LNTH
21.45%
ROA
FOLD
2.48%
LNTH
9.28%

Growth

Revenue Growth
FOLD
23.7%
LNTH
4.0%
Earnings Growth
FOLD
-95.5%
LNTH
--

Financial Health

Debt/Equity
FOLD
1.61
LNTH
0.57
Current Ratio
FOLD
2.84
LNTH
2.7
Quick Ratio
FOLD
1.72
LNTH
2.2

Dividends

Dividend Yield
FOLD
--
LNTH
--
Payout Ratio
FOLD
0.0%
LNTH
0.0%

AI Verdict

FOLD BEARISH

FOLD exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While the company maintains impressive gross margins (88.5%) and revenue growth (23.7%), these are offset by a catastrophic collapse in earnings growth (-95.5% YoY) and negative ROE. The stock is currently trading at a 52-week high despite a bearish technical trend score (10/100) and aggressive insider selling by the CEO and other officers. The disconnect between the current price and the underlying deterministic health metrics suggests a high risk of a price correction.

Strengths
Exceptional gross margins of 88.50%
Strong year-over-year revenue growth of 23.70%
Robust short-term liquidity with a current ratio of 2.84
Risks
Critically low Piotroski F-Score (2/9) signaling financial instability
Severe earnings growth decline of -95.50% YoY
Heavy insider selling with 11 sell transactions and 0 buys
LNTH NEUTRAL

LNTH exhibits strong operational health with a Piotroski F-Score of 7/9 and robust liquidity (Current Ratio 2.70), though it lacks an Altman Z-Score for bankruptcy benchmarking. While the company is highly profitable with an ROE of 21.45% and a consistent track record of earnings beats, the stock trades at a significant premium to its Graham Number ($35.98) and Intrinsic Value ($23.87). The bullish outlook is supported by a low Forward P/E of 12.81 and a positive analyst target of $91.38, but the current price is disconnected from deterministic value metrics.

Strengths
Strong financial health indicated by a Piotroski F-Score of 7/9
Excellent liquidity with a Current Ratio of 2.70 and Quick Ratio of 2.20
High profitability with 21.45% ROE and 61.10% Gross Margin
Risks
Significant valuation gap between current price ($80.59) and Graham Number ($35.98)
Modest year-over-year revenue growth of only 4.00%
Bearish technical trend (0/100) despite recent 6-month recovery

Compare Another Pair

FOLD vs LNTH: Head-to-Head Comparison

This page compares Amicus Therapeutics, Inc. (FOLD) and Lantheus Holdings, Inc. (LNTH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile